ArticleFrontiers in immunology2021
Case Report: Abscopal Effect of Microwave Ablation in a Patient With Advanced Squamous NSCLC and Resistance to Immunotherapy.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 23 citations in OpenAlex.
- Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial.Signal transduction and targeted therapy · 2025Trial
- Thermal modulation enhances antitumour immunity and improves immunotherapy responses in lung cancer.Discover oncology · 2026Review
- Research status and trend of lung cancer ablation therapy: a bibliometric analysis from 2002 to 2025.Journal of thoracic disease · 2026Article
- Defining the abscopal effect in non-small cell lung cancer in the era of immunotherapy and lung ablation treatment: a narrative review.Frontiers in medicine · 2026Review
- Sequential microwave ablation combined with radioactive iodine-125 seed implantation successfully cured multiple metastases of gallbladder cancer: A case report.Oncology letters · 2025Article
- [Progress in the Immune Mechanism of Microwave Ablation Therapy for Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Combining Microwave Ablation With CAR-T-Cell Therapy in Tumor-Bearing Mouse Models.Bio-protocol · 2025Article
- Microwave Ablation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.Thoracic cancer · 2025Article
- Review
- Case Report: Abscopal effect of radiotherapy in a patient with metastatic duodenal adenocarcinoma and resistance to chemoimmunotherapy.Frontiers in immunology · 2025Article
- Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer.Scientific reports · 2024Article
- Tissue Ablation: Applications and Perspectives.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Efficacy and safety of local ablative therapy for patients with NSCLC and coexisting interstitial lung disease.Thoracic cancer · 2024Article
- Microwave ablation enhances the systemic immune response in patients with lung cancer.Oncology letters · 2024Article
- Immunomodulatory effects of microwave ablation on malignant tumors.American journal of cancer research · 2024Review
- Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers.Molecular cancer therapeutics · 2023Review
- Potential biomarkers for predicting immune response and outcomes in lung cancer patients undergoing thermal ablation.Frontiers in immunology · 2023Review
- Engineering the Tumor Immune Microenvironment through Minimally Invasive Interventions.Cancers · 2022Review
- Oligoprogression in non-small cell lung cancer: a narrative review.Journal of thoracic disease · 2022Review
- Rational Nanomedicine Design Enhances Clinically Physical Treatment-Inspired or Combined Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, immunotherapy has been a backbone in the treatment of advanced non-small cell lung cancer (NSCLC) without driver gene mutations. However, only a small proportion of NSCLC patients respond to immune checkpoint inhibitors, and majority of patients with initial response will develop acquired resistance at 5 years, which usually manifests as oligo-progression or oligo-metastases. Evidence from multiple clinical trials indicates that local consolidative therapies could improve the prognosis of oligometastatic NSCLC patients. Herein, we reported a case of advanced squamous lung cancer which showed a durable abscopal effect from microwave ablation after acquired resistance of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.